MA49128A - Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 - Google Patents
Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2Info
- Publication number
- MA49128A MA49128A MA049128A MA49128A MA49128A MA 49128 A MA49128 A MA 49128A MA 049128 A MA049128 A MA 049128A MA 49128 A MA49128 A MA 49128A MA 49128 A MA49128 A MA 49128A
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- pyrimidine derivatives
- derivatives used
- pge2 receptors
- pge2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2017061989 | 2017-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49128A true MA49128A (fr) | 2021-03-17 |
Family
ID=62196584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049128A MA49128A (fr) | 2017-05-18 | 2018-05-17 | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 |
Country Status (32)
Country | Link |
---|---|
US (1) | US11839613B2 (fr) |
EP (1) | EP3625228B1 (fr) |
JP (1) | JP7159215B2 (fr) |
KR (1) | KR102626982B1 (fr) |
CN (1) | CN110612299A (fr) |
AR (1) | AR111808A1 (fr) |
AU (1) | AU2018268311B2 (fr) |
BR (1) | BR112019024105A2 (fr) |
CA (1) | CA3060394A1 (fr) |
CL (1) | CL2019003274A1 (fr) |
CO (1) | CO2019010505A2 (fr) |
CR (1) | CR20190560A (fr) |
CY (1) | CY1124799T1 (fr) |
DK (1) | DK3625228T3 (fr) |
EA (1) | EA201992677A1 (fr) |
ES (1) | ES2887041T3 (fr) |
HR (1) | HRP20211380T1 (fr) |
HU (1) | HUE056382T2 (fr) |
IL (1) | IL270620B2 (fr) |
LT (1) | LT3625228T (fr) |
MA (1) | MA49128A (fr) |
MX (1) | MX2019013638A (fr) |
PE (1) | PE20191811A1 (fr) |
PH (1) | PH12019502564A1 (fr) |
PL (1) | PL3625228T3 (fr) |
PT (1) | PT3625228T (fr) |
RS (1) | RS62398B1 (fr) |
SG (1) | SG11201908097YA (fr) |
SI (1) | SI3625228T1 (fr) |
TW (1) | TW201900178A (fr) |
UA (1) | UA125124C2 (fr) |
WO (1) | WO2018210988A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
TW201900179A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物 |
CA3063788A1 (fr) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Derives de pyrimidine |
MA49126B1 (fr) | 2017-05-18 | 2021-10-29 | Idorsia Pharmaceuticals Ltd | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 |
WO2021060281A1 (fr) * | 2019-09-24 | 2021-04-01 | Agc株式会社 | Antagoniste double des récepteurs ep2/ep4 de la prostaglandine e2 |
KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
CN113248354B (zh) * | 2021-07-07 | 2022-04-22 | 山东国邦药业有限公司 | 一种氟氯苯乙酮的合成方法 |
CN114539193A (zh) * | 2022-01-20 | 2022-05-27 | 海南普利制药股份有限公司 | 一种盐酸胺碘酮中间体的制备方法 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
AU3445100A (en) | 2000-03-24 | 2001-10-08 | Pharmagene Lab Ltd | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
WO2003087061A1 (fr) | 2002-04-12 | 2003-10-23 | Pfizer Japan Inc. | Composes de pyrazole en tant qu'agents anti-inflammatoires et analgesiques |
BR0309305A (pt) | 2002-04-12 | 2005-02-15 | Pfizer | Compostos de imidazol como agentes antiinflamatórios e analgésicos |
BR0311247A (pt) | 2002-05-23 | 2005-03-15 | Theratechnologies Inc | Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2 |
WO2004067524A1 (fr) | 2003-01-29 | 2004-08-12 | Pharmagene Laboratories Limited | Antagonistes aux recepteurs ep4 |
EP1661896A4 (fr) | 2003-08-26 | 2008-07-16 | Teijin Pharma Ltd | Derive de pyrrolopyrimidinethione |
BRPI0414130B8 (pt) | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
EP1678147B1 (fr) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
CA2565813C (fr) | 2004-05-04 | 2010-10-26 | Pfizer Inc. | Composes methylaryl- ou heteroarylamides substitues |
JP4054369B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | オルト置換アリールまたはヘテロアリールアミド化合物 |
HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
EP1885722B1 (fr) | 2005-05-19 | 2011-11-16 | Merck Canada Inc. | Derives de quinoleine a titre d'antagonistes de ep4 |
WO2006128129A2 (fr) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Traitement anticancereux |
AR060403A1 (es) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
WO2007121578A1 (fr) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Dérivés d'indolamide comme antagonistes du récepteur ep4 |
AU2007260529B2 (en) | 2006-06-12 | 2012-04-19 | Merck Canada Inc. | Indoline amide derivatives as EP4 receptor ligands |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008059A1 (fr) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Agents anti-cancer et leurs utilisations |
PT2044056E (pt) | 2006-07-14 | 2012-12-05 | Novartis Ag | Derivados de pirimidina como inibidores de alk-5 |
JP5259592B2 (ja) | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ep4受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
WO2008039882A1 (fr) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2 |
AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
CN101641325A (zh) | 2007-03-26 | 2010-02-03 | 安斯泰来制药株式会社 | 鸟氨酸衍生物 |
WO2008116304A1 (fr) | 2007-03-26 | 2008-10-02 | Merck Frosst Canada Ltd. | Dérivés de naphtalène et quinoléine sulfonylurée comme antagonistes du récepteur ep4 |
EP2014657A1 (fr) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine en tant que modulateurs du récepteur EP2 |
EP2460787A1 (fr) | 2007-07-03 | 2012-06-06 | Astellas Pharma Inc. | Composés d'amide et leur utilidsation comme anagonistes de la PGE2. |
NZ584454A (en) | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases |
CA2714743C (fr) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines et triazines en tant que modulateurs d'amide d'acide gras hydrolase |
SI2565191T1 (sl) | 2008-05-14 | 2014-12-31 | Astellas Pharma Inc. | Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije |
US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
CA2733247C (fr) | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Derives d'amides heterocycliques en tant qu'antagonistes du recepteur ep4 |
WO2010032123A1 (fr) | 2008-09-19 | 2010-03-25 | Biotechnology Research Corporation Limited | Composés triterpénoïdes et procédés pour les utiliser |
US8685999B2 (en) | 2008-09-25 | 2014-04-01 | Merck Sharp & Dohme Corp. | Beta carboline sulphonylurea derivatives as EP4 receptor antagonists |
US8906914B2 (en) * | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
AU2010321905A1 (en) | 2009-11-23 | 2012-05-24 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
CA2798578C (fr) | 2010-05-21 | 2015-12-29 | Chemilia Ab | Nouveaux derives de pyrimidine |
MX2013003162A (es) | 2010-09-21 | 2013-05-06 | Eisai R&D Man Co Ltd | Composicion farmaceutica. |
AU2011309028B2 (en) | 2010-09-29 | 2016-03-17 | Nb Health Laboratory Co. Ltd. | Antibody against human prostaglandin E2 receptor EP4 |
CA2816679A1 (fr) | 2010-11-17 | 2012-05-24 | Novartis Ag | Composes 3-(aminoaryl)-pyridine |
WO2012066065A1 (fr) | 2010-11-17 | 2012-05-24 | Novartis Ag | Composés phényl-hétéroaryl amine et leurs utilisations |
ES2545110T3 (es) | 2010-12-10 | 2015-09-08 | Rottapharm Biotech S.R.L. | Derivados de piridinamida como antagonistas del receptor EP4 |
WO2012103071A2 (fr) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Composés et compositions |
RU2013147417A (ru) | 2011-03-24 | 2015-04-27 | Кемилиа Аб | Новые производные пиримидина |
EP2702043A1 (fr) | 2011-04-29 | 2014-03-05 | Exelixis, Inc. | Inhibiteurs de la forme inductible de la 6-phosphofructose-2-kinase |
US9518044B2 (en) | 2011-06-20 | 2016-12-13 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
ES2559513T3 (es) | 2011-07-04 | 2016-02-12 | Rottapharm Biotech S.R.L. | Derivados de amina cíclica como antagonistas del receptor EP4 |
EP2554662A1 (fr) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Procédés pour le traitement de maladies rétiniennes dégénératives |
US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
EP2841428B1 (fr) * | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Inhibiteurs d'adn pk |
TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
EP2711364A1 (fr) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl ou benzimidazolyl)amino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer |
CA2888338C (fr) | 2012-11-27 | 2021-07-20 | Thomas Helledays Stiftelse For Medicinsk Forskning | Inhibiteurs mth1 pour le traitement du cancer |
UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
EP2765128A1 (fr) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Benzamides substitués présentant une activité vis-à-vis de récepteurs EP4 |
TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫-1h-異喹啉化合物 |
MY173564A (en) | 2013-05-30 | 2020-02-04 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
AU2014279113B2 (en) | 2013-06-12 | 2018-04-12 | Kaken Pharmaceutical Co., Ltd. | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient |
CN105705489B (zh) | 2013-09-04 | 2019-04-26 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
WO2015044900A1 (fr) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Composés immunomodulateurs thérapeutiques |
RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
BR112016008423B1 (pt) * | 2013-10-17 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Composto, composição farmacêutica compreendendo o mesmo e seu uso |
CN105793242B (zh) | 2013-12-17 | 2018-02-16 | 伊莱利利公司 | 苯氧基乙基环状胺衍生物及其作为ep4受体调节剂的活性 |
EA028675B1 (ru) | 2013-12-17 | 2017-12-29 | Эли Лилли Энд Компани | Соединения диметилбензойной кислоты |
TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ep4配體之新穎苯并咪唑衍生物 |
TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
WO2015167825A1 (fr) | 2014-04-29 | 2015-11-05 | Emory University | Antagonistes du récepteur ep2 des prostaglandines, dérivés, compositions et utilisations associés |
CN110354266A (zh) | 2014-05-23 | 2019-10-22 | 卫材 R&D 管理有限公司 | 用于治疗癌症的组合疗法 |
EP3151833A4 (fr) | 2014-06-04 | 2018-01-10 | Thomas Helledays Stiftelse För Medicinsk Forskning | Inhibiteurs de mth1 destinés au traitement des états inflammatoires et auto-immuns |
CA2949793C (fr) | 2014-06-19 | 2024-02-27 | Ariad Pharmaceuticals, Inc. | Composes heteroaryle d'inhibition de la kinase |
WO2016021742A1 (fr) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr4 |
NZ733575A (en) | 2015-01-09 | 2022-10-28 | Ono Pharmaceutical Co | Tricyclic spiro compound |
WO2017014323A1 (fr) | 2015-07-23 | 2017-01-26 | Takeda Pharmaceutical Company Limited | Dérivés substitués en 1 de 1,2,3,4-tétrahydro-1,7-naphtyridin-8-amine et leur utilisation comme antagonistes du récepteur ep4 |
CN108473497B (zh) | 2015-10-16 | 2021-09-10 | 卫材R&D 管理有限公司 | Ep4拮抗剂 |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
JP7033583B2 (ja) | 2016-07-13 | 2022-03-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | ゲノム編集効率を高めるための方法、組成物及びキット |
CA3063788A1 (fr) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Derives de pyrimidine |
TW201900179A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物 |
UA124748C2 (uk) | 2017-05-18 | 2021-11-10 | Ідорсія Фармасьютікалз Лтд | N-заміщені індольні похідні |
MA49126B1 (fr) | 2017-05-18 | 2021-10-29 | Idorsia Pharmaceuticals Ltd | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 |
-
2018
- 2018-05-17 TW TW107116710A patent/TW201900178A/zh unknown
- 2018-05-17 UA UAA201911976A patent/UA125124C2/uk unknown
- 2018-05-17 KR KR1020197037039A patent/KR102626982B1/ko active IP Right Grant
- 2018-05-17 SG SG11201908097Y patent/SG11201908097YA/en unknown
- 2018-05-17 RS RS20211222A patent/RS62398B1/sr unknown
- 2018-05-17 MX MX2019013638A patent/MX2019013638A/es unknown
- 2018-05-17 BR BR112019024105-1A patent/BR112019024105A2/pt unknown
- 2018-05-17 CR CR20190560A patent/CR20190560A/es unknown
- 2018-05-17 SI SI201830403T patent/SI3625228T1/sl unknown
- 2018-05-17 EA EA201992677A patent/EA201992677A1/ru unknown
- 2018-05-17 AU AU2018268311A patent/AU2018268311B2/en not_active Ceased
- 2018-05-17 ES ES18725498T patent/ES2887041T3/es active Active
- 2018-05-17 CA CA3060394A patent/CA3060394A1/fr active Pending
- 2018-05-17 DK DK18725498.2T patent/DK3625228T3/da active
- 2018-05-17 CN CN201880030982.5A patent/CN110612299A/zh active Pending
- 2018-05-17 HU HUE18725498A patent/HUE056382T2/hu unknown
- 2018-05-17 US US16/614,209 patent/US11839613B2/en active Active
- 2018-05-17 AR ARP180101313A patent/AR111808A1/es unknown
- 2018-05-17 WO PCT/EP2018/062844 patent/WO2018210988A1/fr unknown
- 2018-05-17 MA MA049128A patent/MA49128A/fr unknown
- 2018-05-17 JP JP2019563493A patent/JP7159215B2/ja active Active
- 2018-05-17 LT LTEPPCT/EP2018/062844T patent/LT3625228T/lt unknown
- 2018-05-17 EP EP18725498.2A patent/EP3625228B1/fr active Active
- 2018-05-17 PT PT187254982T patent/PT3625228T/pt unknown
- 2018-05-17 PL PL18725498T patent/PL3625228T3/pl unknown
- 2018-05-17 PE PE2019002395A patent/PE20191811A1/es unknown
-
2019
- 2019-09-26 CO CONC2019/0010505A patent/CO2019010505A2/es unknown
- 2019-11-13 IL IL270620A patent/IL270620B2/en unknown
- 2019-11-14 CL CL2019003274A patent/CL2019003274A1/es unknown
- 2019-11-15 PH PH12019502564A patent/PH12019502564A1/en unknown
-
2021
- 2021-08-30 HR HRP20211380TT patent/HRP20211380T1/hr unknown
- 2021-10-06 CY CY20211100870T patent/CY1124799T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49128A (fr) | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 | |
MA49126A (fr) | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 | |
MA54169A (fr) | Tolyles substitués utilisés en tant que fongicides | |
MA54452A (fr) | Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a | |
MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
MA47120A (fr) | Dérivés pyridine utilisés en tant qu'immunomodulateurs | |
MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
MA43512A (fr) | Composés hétérocycliques utiles en tant que modulateurs du tnf alpha | |
MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
MA47086A (fr) | Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase | |
MA44502A (fr) | Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA55046A (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
MA48987A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA41341A (fr) | Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
CL2015002121A1 (es) | Modulares de receptores nmda de espiro-lactama y sus usos. | |
MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
MA48943A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
MA47370A (fr) | Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines | |
MA42810A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue |